Clinical Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib and Thalidomide for Treating Patients with Multiple Myeloma.

Chang-Sheng LI; Ye JI; Wan-Ping ZHANG; Li-Ping FU

Return

Clinical Efficacy and Safety of Different Doses of Dexamethasone Combined with Bortezomib and Thalidomide for Treating Patients with Multiple Myeloma.

Author: Chang-Sheng LI ¹ ; Ye JI ² ; Wan-Ping ZHANG ³ ; Li-Ping FU ⁴
Author Information

1. Second Ward of Oncology Department,Nanyang City Center Hospital, Nanyang 473009, Henan Province, China.
2. Second Department of Oncology,Nanyang City Center Hospital, Nanyang 473009, Henan Province, China.
3. Department of Clinical Laboratorial Examination, Nanyang City Center Hospital, Nanyang 473009, Henan Province, China.
4. Medical Services Section, Nanyang City Center Hospital, Nanyang 473009, Henan Province, China. E-mail:lchshdoctor@2008.sina.com.
Publication Type:Journal Article
MeSH: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Multiple Myeloma; Thalidomide; Treatment Outcome
From: Journal of Experimental Hematology 2018;26(3):836-841
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo study the clinical efficacy and safety of dexamethasone of different doses combined with bortezomib and thalidomide for treatment of primary multiple myeloma.
METHODSNinety-six patients with multiple myeloma from January 2013 to January 2014 were randomly divided into group A (high-dose dexamethasone + bortezomib + thalidomide, 32 cases), group B (low-dose dexamethasone + bortezomib + thalidomide, 32 cases) and group C (placebo + bortezomib + thalidomide, 32 cases). The clinical efficacy and safety of patients was compared among 3 groups.
RESULTSThe overall remission rate (ORR) in group A and B was significantly higher than that in group C (P<0.05), but the ORR was not significant difference between group A and group B (P>0.05). After treatment, the KPS and RNS score in 3 groups were significantly higher and lower than those before treatment, respectively; the KPS score in group A and B was significantly higher than that in group C (P<0.05), the RNS score in group A and B was significantly lower C (P<0.05). After treatment, the positive expression rates of CD38, CD56 and CD138 as well as small residual lesion (SRL) positive rate in 3 grops were significantly lower than those before treatment, but the positive expression rate of CD19 was significantly higher that before treatment; the positive expression rates of CD38, CD56 and CD138 as well as SRL positive rate in group A and B were significantly lower thant those in group C, while the positive expression rate of CD19 was significantly higher that in group C (P<0.05), but the positive expression rates of CD19, CD38, CD56 and CD138 as well as SRL positive rate were not significantly different between group A and B (P>0.05). The incidence of fatigue, rash, peripheral neuropathy, anlmia, granulocyte deficiance and so on in group B and C was significantly lower than that in group A(P<0.05), but the difference in group B and C was not significant (P>0.05).
CONCLUSIONThe therapeutic efficacy of different doses of dexamethasone combined with bortezomib and thalidomide for patients with multiple myeloma is similar, can obviously enhance remission rate, prolong the survival time, promote life quality, but the incidence of adverse reactions in low dose dexamethason rigemen is significantly reduced, and the safety is better.